Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer

(2013) F. E. Vera-Badillo et al.   ANNALS OF ONCOLOGY

Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study

(2013) J. Kankesan et al.   Current Oncology

Adrenocortical carcinoma: A population-based study on incidence and survival in the Netherlands since 1993

(2013) Thomas M.A. Kerkhofs et al.   EUROPEAN JOURNAL OF CANCER

Evaluation of Treatment Benefit in Journal of Clinical Oncology

(2013) Pamela J. Goodwin et al.   JOURNAL OF CLINICAL ONCOLOGY

Hospital and Surgeon Volume in Relation to Survival After Esophageal Cancer Surgery in a Population-Based Study

(2013) Maryam Derogar et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient Income Level and Cancer Clinical Trial Participation

(2013) Joseph M. Unger et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

(2013) Sarah C. Darby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization and Outcomes of Small Cell Carcinoma of the Bladder Using the Surveillance, Epidemiology, and End Results Database

(2012) David Schreiber et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Is It Time for Medicine-Based Evidence?

(2012) John Concato   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

(2012) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer

(2012) Abdullah K. Altwairgi et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Effectiveness Research in Oncology Methodology: Observational Data

(2012) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Effectiveness of Oxaliplatin vs Non–Oxaliplatin-containing Adjuvant Chemotherapy for Stage III Colon Cancer

(2012) Hanna K. Sanoff et al.   JNCI-Journal of the National Cancer Institute

Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points

(2011) A. Kay et al.   ANNALS OF ONCOLOGY

The impact of audit and feedback on nodal harvest in colorectal cancer

(2011) Geoffrey A Porter et al.   BMC CANCER

Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Administration

(2011) Mary Beth Landrum et al.   CANCER

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Compendium of Unpublished Phase III Trials in Oncology: Characteristics and Impact on Clinical Practice

(2011) Vincent C. Tam et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

(2011) Anil K. Chaturvedi et al.   JOURNAL OF CLINICAL ONCOLOGY

Influence of Race, Insurance, Socioeconomic Status, and Hospital Type on Receipt of Guideline-Concordant Adjuvant Systemic Therapy for Locoregional Breast Cancers

(2011) Xiao-Cheng Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reporting and Interpretation of Randomized Controlled Trials With Statistically Nonsignificant Results for Primary Outcomes

(2010) Isabelle Boutron   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Adoption of Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer: A Population-Based Outcomes Study

(2010) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer

(2010) Matthew R. Cooperberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Reporting of Serious Adverse Drug Reactions of Targeted Anticancer Agents in Pivotal Phase III Clinical Trials

(2010) Bostjan Seruga et al.   JOURNAL OF CLINICAL ONCOLOGY

Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer

(2009) B. Seruga et al.   ANNALS OF ONCOLOGY

Clinical benefit in oncology trials: Is this a patient-centred or tumour-centred end-point?

(2009) Pavlo Ohorodnyk et al.   EUROPEAN JOURNAL OF CANCER

Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies

(2009) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY

Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings

(2009) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY

Generalizing the Results of Cancer Clinical Trials

(2009) Ralph M. Meyer   JOURNAL OF CLINICAL ONCOLOGY

Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception

(2008) Leonard B. Saltz   JOURNAL OF CLINICAL ONCOLOGY

Evolution of the Randomized Controlled Trial in Oncology Over Three Decades

(2008) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY